Catalog: hAP7027 $775 US | $970 International
hAstroPro™ Human Astrocyte Cells are derived from human pluripotent stem cell line h9 (NIH registry number 0062) and are the first highly characterized hESC derived CNS support cell type commercially available. hAstroPro™ cells are derived using a chemically defined method that enables shortened differentiation and scaled uniform production.
Ideal for use in studies of glial development and for use in co-culture systems with ArunA's NeuroNet™ Pure Human Neurons.
Cell Type: Astrocytes
Inhibition of DNA methyltransferases and histone deacetylases induces astrocytic differentiation of neural progenitors.
Working bank pathogen testing: This lot was derived from the H9 hESC line that has been tested for Hepatitis B, Hepatitis C, HIV-1, HIV-2, HTLV-I/II, HSV1, HSV2, EBV, and CMV. The H9 cell line has been tested and shown to be negative (performed by GIVF Laboratories). Cells are also tested for sterility and mycoplasma contamination.
For additional information contact us at firstname.lastname@example.org or call 706-542-4941.
7 day Co culture of hN2™ Differentiated Neuronal Cells and hAstroPro™ Human Astrocyte Cells
hAstroPro More representative cellular and computational model
hAstroPro use in metabolomics developmental neurotoxicity assay.
A vast number of chemical entities, ranging from pesticides to compounds of therapeutic interest, remain untested for potential toxic outcomes on human neural development. Current methods for evaluating developmental neurotoxicity (DNT) rely heavily on animal based testing and non-uniform cell lines, are often prohibitively expensive, and provide suboptimal predictive value. There is thus a need for rapid, cost effective, in vitro methods to identify such chemicals. To fill this critical gap we evaluated a robust, species representative and physiologically relevant cellular system, combined with high content imaging (HCI) and metabolomics, to address human DNT. Scalable and uniform populations of undifferentiated neural progenitor cells (hNP1TM), and differentiated neurons (hN2TM) and astrocytes (hAstroProTM), derived from human embryonic stem cells (hESC) were used to represent a neurodevelopmental continuum and evaluated for toxin induced changes in neurite outgrowth, metabolomic signatures and viability. To address developmental stage specific neurotoxicity, Bis-1, a known neurotoxin, was applied to cultures pre or post neuronal differentiation, as well as in neuron-astrocyte co-cultures to represent complex brain tissue more accurately.
Your success is important to us. If you have technical questions regarding the use of your ArunA Biomedical products, we have your Tech Support Team ready. Just send an email to: email@example.com, and a cell culture expert will assist you.
Your success is our success!
Products are to be used for research purposes only, not for use in diagnostic or therapeutic applications. It is prohibited to sell, modify for sale or use ArunA's products for commercial purposes without the express written consent of ArunA Biomedical.
ArunA has entered into a technology licensing agreement with the University of Georgia Research Foundation (UGARF) that enables the company to commercialize adherent monolayer neural cell technology developed at the University. The license allows the company exclusive worldwide rights to develop and commercialize neural cells derived from human pluripotent stem cells including hPSC and human iPSC.
ArunA has also entered into a research and commercialization license with the Wisconsin Alumni Research Foundation (WARF) for nonexclusive rights to their embryonic stem cell patents in research applications.
Patent US 6,200,806
Patent US 8,178,089